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Socioeconomic inequalities in cancer survival in Scotland
1986–2000
LG Shack*,1,2, B Rachet1, DH Brewster3 and MP Coleman1
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We analysed trends in 5-year survival of the 18 commonest cancers in Scotland diagnosed between 1986 and 2000 and followed up
to 2004 in each of five deprivation groups based on patients postcode of residence at diagnosis. We estimated relative survival up to
5 years after diagnosis, adjusting for the different background mortality in each deprivation group by age, sex and calendar period. We
estimated trends in overall survival and in the deprivation gap in survival up to 2004. Five-year survival improved for all malignancies
except bladder cancer and was associated with a widening in the deprivation gap in survival. For 25 of 30 cancer–sex combinations
examined, 5-year survival was lower among more deprived patients diagnosed during 1996–2000, and the deprivation gap in survival
had widened since 1986–1990 for 15 of these 25 cancers, similar to the trends seen in England and Wales.
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Cancer survival is known to vary by socioeconomic level in many
parts of the world (Kogevinas and Porta, 1997; Woods et al, 2006).
In England and Wales, such inequalities have been demonstrated
for most adults diagnosed with cancer during 1971–1990
(Coleman et al, 1999). Survival improved for adults diagnosed
with the 20 most common cancers in England and Wales during
the period 1986–1999, but socioeconomic inequalities in survival
widened (Coleman et al, 2004).
In Scotland, despite substantial recent improvements in survival
(Scottish Cancer Intelligence Unit, 2004), cancer mortality has
historically been higher, and survival lower, than in England and
Wales (Coleman et al, 2003; Quinn et al, 2005). To the extent that
the link between survival and socioeconomic status is causal, the
lower survival in Scotland may be partly attributable to a lower
average socioeconomic level (Griffiths and Fitzpatrick, 2001).
Socioeconomic inequalities in cancer survival in Scotland have
been examined, but to our knowledge, trends in these inequalities
have not been evaluated. We investigated socioeconomic differ-
ences in cancer survival among patients diagnosed in Scotland
during 1986–2000, and trends in these inequalities over time.
MATERIALS AND METHODS
We examined the data for 357 658 adults (aged 15–99 years)
diagnosed with a first, invasive, primary, malignant neoplasm
(excluding nonmelanoma skin cancer, ICD-10 C00-C97 excluding
C44) in Scotland between 1 January 1986 and 31 December 2000
(the most recent year of complete data available at the time) and
registered at the Scottish Cancer Registry. Incident cases were
linked to death details provided by the General Register Office for
Scotland. Data were extracted for analysis on 13 April 2005. The
vital status was considered to be known for all patients up to 31
December 2004. Patients identified from a death certificate only
were excluded (3.4% of all registrations). About 8.5% of records
(31 982) with a second or later tumours were excluded.
Patients were matched to socioeconomic categories based on
their postcode of residence at diagnosis, using the 1991 census-
derived Carstairs Deprivation Index Score (Carstairs, 1995) for
those diagnosed during 1986–1995 and the Scottish Indices of
Multiple Deprivation (IMD) 2004 score for those diagnosed during
1996– 2000 (General Register Office for Scotland, 2006). Socio-
economic category was based on the geographic level of postcode
sector (n¼ 4660) for Carstairs and data zone (n¼ 770) for IMD.
The combined IMD score was used to assign deprivation, rather
than only the income domain score, because this was consistent
with the Carstairs deprivation group and is the system used by the
Scottish Cancer Registry (Measuring Deprivation Subgroup, 2004).
The five deprivation categories were derived from quintiles of the
national distribution of area deprivation scores in Scotland.
Methods for analysis have previously been published (Coleman
et al, 2004). Briefly, relative survival at 5 years after diagnosis was
estimated for patients diagnosed with cancer and resident in
Scotland. Relative survival is the ratio of observed survival of
cancer patients and the survival that would have been expected if
the patients had had the same age-, deprivation- and sex-specific
mortality in each period as the general population (Berkson and
Gage, 1950). Period life tables by single year of age (up to 99 years),
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sex and deprivation category were derived from the numbers of
deaths for 1990–1992 and 2000– 2002 (General Register Office for
Scotland, 2006). Corresponding population denominators were
drawn from the 1991 and 2001 census populations from the
General Register Office for Scotland (2006).
Relative survival was estimated for each of the 20 most common
cancers by deprivation category and sex for each of three periods
of diagnosis; 1986–1990, 1991–1995 and 1996–2000. The 1990–
1992 life tables were used to estimate background mortality for
patients dying in 1986–1995 and the 2000–2002 life tables for
those dying in 1996– 2004.
We used the maximum likelihood approach for individual
records (Este`ve et al, 1990) to estimate relative survival using an
algorithm developed for similar analyses (Coleman et al, 2004) in
STATA software (Statacorp, 2004). Survival probabilities were
estimated monthly for the first 6 months, then quarterly up to 1
year, then every 6 months from 1 year to 5 years. Survival for
cancer of the larynx was estimated using monthly intervals up to 6
months, then 6 monthly up to 3 years and yearly up to 5 years.
The cohort approach was used for patients diagnosed during
1986– 1990 and 1991–1995, while 5-year survival was based on the
complete approach for those diagnosed in 1996–2000.
Variance-weighted linear regression (Grizzle et al, 1969) was
used to estimate temporal change in survival and the survival
gradient across deprivation categories. For each time period, the
‘deprivation gap’ in survival was estimated as the absolute fitted
difference between 5-year survival in the most deprived and the
most affluent categories, estimated from the regression model
(Coleman et al, 2004; Figure 1). The deprivation gap is described as
negative if survival is lower in the most deprived than the most
affluent group. Temporal change in the deprivation gap was
estimated by inclusion in the model of an interaction term between
period of diagnosis and deprivation group.
Survival could not be reliably estimated within deprivation
groups for cancers of the pancreas, testis or larynx (women), due
to small numbers of cases and/or deaths in some intervals
after diagnosis. Survival is high for testicular cancer, and for
laryngeal cancer in women, and very few deaths occurred 3–5
years after diagnosis. Most pancreatic cancer patients died within a
year of diagnosis.
RESULTS
Five-year relative survival improved for most malignancies
during the period 1986–2000 (Table 1). It increased rapidly, at
7–8% every 5 years, for cancers of the breast (women) and rectum
(both sexes), and for all leukaemias combined (both sexes).
Five-year survival from prostate cancer rose by an average of 11%
every 5 years.
For patients diagnosed during 1996– 2000, the deprivation gap
in survival was negative (survival lower among the deprived than
the affluent) for 25 of the 30 cancer–sex combinations, and
statistically significant for 9 of these: colon (both sexes), rectum
(women), larynx (men), lung (men), melanoma (women), breast
(women), prostate and bladder (men; Table 1).
The deprivation gap in survival was negative for 15 of the 25
cancers diagnosed among patients during 1996–2000, the depriva-
tion gap had widened significantly since 1986. By contrast, the
deprivation gap in survival became significantly smaller over
the same period for oesophagus (men), stomach (men), brain
(men), non-Hodgkin’s lymphoma (men), myeloma (women) and
leukaemia (men).
Differences in 5-year survival patterns between men and women
were observed for all 12 cancers included in the analysis that arise
in both sexes. The deprivation gap widened for all these cancers
among women, but it was almost stable among men. So, whereas
women diagnosed during 1986–1990 experienced a clear survival
advantage over men (data not shown), this advantage having
disappeared for those diagnosed during 1996–2000.
The deprivation gap widened for uterine cancer, but not for
cancers of the breast (women), ovary or cervix. By contrast, the
deprivation gap widened by about 3% every 5 years for cancers of
the larynx (men) and prostate, leading to large socioeconomic
differences in survival by 1996–2000.
Bladder cancer survival decreased over time in both sexes, but
women had significantly lower survival than men. The deprivation
gap in survival widened by about 4% every 5 years, reaching
7% for patients diagnosed during 1996– 2000.
Five-year survival from brain tumours in women was 16%
during 1986–1990, but fell from 20% for 1991–1995 to 17% for
women diagnosed during 1996–2000. Survival from brain tumours
in men improved more in the poor than the rich, so that the
deprivation gap had actually reversed (þ 4% in 1996–2000) with
higher survival in the most deprived group.
Survival for non-Hodgkin’s lymphoma and myeloma improved
by about 5% every 5 years, and leukaemia survival improved
even more rapidly, by about 8% every 5 years. No significant
socioeconomic difference in survival was seen for any of the
haematological malignancies.
DISCUSSION
For cancer patients diagnosed in Scotland during 1996–2000,
5-year survival was lower among those who lived in more deprived
areas. The socioeconomic inequality in survival worsened over the
15-year period 1986–2000, particularly among women.
Socioeconomic differences in cancer survival have been
observed in many countries (Kogevinas and Porta, 1997; Ward
et al, 2004), including the Netherlands (Schrijvers et al, 1995a),
Canada (Mackillop et al, 1997), England and Wales (Coleman et al,
1999), Scotland (Scottish Cancer Intelligence Unit, 2000) and the
United States (Singh et al, 2003). In England and Wales, recent
improvements in survival have been more marked in affluent
groups, actually widening the socioeconomic inequality in survival
(Coleman et al, 2004). Our findings are broadly consistent
with these studies, both on socioeconomic inequalities in survival
and worsening of those inequalities over time. It remains to be
determined whether the deprivation gap in survival is widening in
other countries.
Further investigation is required, not only to identify the causes
of socioeconomic inequality in survival, but also to find out why
the inequality is becoming worse, not better.
We assumed linearity when modelling the association between
survival and deprivation (five categories), and secular trend in the
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Figure 1 Fitted deprivation gap in 5-year relative survival (%): colon
cancer, Scotland, men diagnosed during 1996–2000.
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Table 1 Patterns and trends in 5-year relative survival (%) and the deprivation gap in survival (%), with 95% confidence intervals (CIs): selected cancers, adults (aged 15–99 years) diagnosed in Scotland,
1986–2000
Five-year relative survival (%) Deprivation gap in 5-year survival (%)a
Patients diagnosed during 1996–
2000
Average change (%) every 5 years over the period
1986–2000b
Patients diagnosed during
1996–2000
Average change (%) every 5 years
over the period 1986–2000
Malignancy
No. of
patients
Five-year
survival (%) 95% CI No. of patients Change (%) 95% CI
Deprivation
gap (%) 95% CI Change (%) 95% CI
Oesophagus
Men 2109 10.1 8.7–11.6 6302 2.3c 1.5–3.2 0.4 4.6 to 3.9 1.1c 0.5–1.8
Women 1424 9.8 8.2–11.6 4666 0.7 0.5 to 1.8 4.6 9.3 to 0.2 2.4c 3.2 to 1.5
Stomach
Men 2583 15.5 13.9–17.1 9586 2.7c 1.4–3.9 1.5 2.8 to 5.8 0.8c 0.1 to 1.4
Women 1768 16.1 14.2–18.1 6479 2.4c 1.4–3.5 2.7 7.8 to 2.5 2.6c 3.5 to 1.8
Colon
Men 4969 50.8 49.0–52.4 15 409 4.6c 3.2–6.0 5.7c 10.1 to 1.2 4.4c 5.2 to 3.5
Women 5061 51.0 49.4–52.6 17 216 4.9c 3.7–6.1 6.1c 10.2 to 1.9 2.4c 3.2 to 1.6
Rectum
Men 3190 53.0 50.9–55.1 9506 7.8c 6.1–9.5 5.3 10.7 to 0.2 0.7 1.8 to 0.4
Women 2227 56.0 53.4–58.5 7291 8.1c 5.6–10.6 8.0c 14.5 to 1.5 2.9c 4.1 to 1.7
Larynx
Men 1128 67.3 63.7–70.6 3571 2.9 0.9 to 6.7 10.8c 19.9 to 1.8 3.2c 5.0 to 1.4
Lung
Men 12 055 7.1 6.6–7.6 43 414 0.3c 0.1–0.6 1.6c 3.1 to 0.1 0.6c 0.9 to 0.3
Women 8796 8.1 7.5–8.7 26 707 0.8c 0.0–1.7 1.5 3.3 to 0.4 1.2c 1.5 to 0.9
Melanoma
Men 1266 85.2 82.5–87.6 3671 4.0c 1.3–6.7 5.9 12.3 to 0.5 1.3 0.1 to 2.8
Women 1766 94.6 92.8–95.9 5511 1.4c 0.2–2.6 4.0c 7.6 to 0.5 1.9c 2.8 to 1.1
Breast
Women 16 092 81.6 80.8–82.3 49 910 6.8c 5.9–7.7 4.1c 6.0 to 2.2 0.2 0.6 to 0.2
Cervix
Women 1654 70.9 68.3–73.2 6265 3.7c 1.8–5.5 4.6 10.8 to 1.6 0.2 1.0 to 1.3
Uterus
Women 1930 81.2 78.8–83.3 5821 2.9c 0.5–5.3 5.2 10.7 to 0.3 4.7c 5.8 to 3.5
Ovary
Women 2869 41.1 39.1–43.1 9162 5.3c 3.4–7.3 0.4 5.6 to 4.8 0.8 0.2 to 1.7
Prostate
Men 9370 72.0 70.7–73.4 26 673 10.8c 8.4–12.7 6.9c 10.3 to 3.4 2.9c 3.7 to 2.2
Bladder
Men 3081 62.6 60.2–64.8 12 139 1.5 5.1 to 2.2 6.7c 12.6 to 0.8 4.0c 5.1 to 3.0
Women 1451 51.8 48.6–54.9 5521 2.5 6.0 to 1.0 7.3 15.4 to 0.7 3.9c 5.3 to 2.4
Kidney
Men 1532 44.1 41.2–47.0 4612 2.2 0.3 to 4.6 5.2 12.8 to 2.4 3.1c 4.6 to 1.5
Women 1066 45.9 42.4–49.3 3240 5.4c 3.2–7.6 4.8 13.8 to 4.2 0.3 1.4 to 2.1
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deprivation gap in survival (three time periods). Flexible functions
which allow nonlinear relationships were used to test this
assumption (Royston and Ambler, 1998), but no significant
departure from linearity was detected.
In a study of breast cancer survival using ecological deprivation
indices in England and Wales, the size of geographic unit was
found to be more important than the choice of deprivation index
(Woods et al, 2005). The socioeconomic status assigned to a given
postcode sector may also change over time, but a Scottish study
found that 80% of postcode sectors in Scotland remained in the
same category or only shifted by one socioeconomic group
between censuses (Measuring Deprivation Subgroup, 2004).
A similar study carried out in England and Wales was based
only on the income domain of the IMD, because health-related
factors are a component part (if small) of the overall index
(Coleman et al, 2004). The complete IMD was recommended for
the analysis of Scottish Cancer Registry data, however, because the
differential impact was small (Measuring Deprivation Subgroup,
2004).
Possible explanations for socioeconomic variations in survival
include variations in comorbidity (Schrijvers et al, 1997), stage at
diagnosis (Schrijvers et al, 1995b; Ionescu et al, 1998; Brewster
et al, 2001) and treatment (Campbell et al, 2002; Hole and
McArdle, 2002; Jack et al, 2006). Only a few studies have adjusted
for these factors, or examined their interaction with deprivation.
The inequalities in survival have frequently been attributed to
more deprived patients presenting at a later clinical stage, but even
after adjustment for clinical stage at diagnosis, deprivation
differences in survival persist (Schrijvers et al, 1995a, b; Campbell
et al, 2002). Treatment access has also been seen to vary by
socioeconomic factors (Madison et al, 2004). However, to our
knowledge, only one study has evaluated changes over time in
deprivation-specific survival and in the deprivation gap (Coleman
et al, 2004). Temporal changes in prognostic factors that might
explain the widening deprivation gap in survival should be
investigated, for example, trends in socioeconomic differences in
comorbidity, or in access to health care.
Deprivation-specific survival cannot be directly compared
between England and Wales and Scotland because the deprivation
measures are not defined identically in each country, but
comparison of relative changes can be evaluated. Overall, Scotland
has higher levels of deprivation than England and Wales (Griffiths
and Fitzpatrick, 2001). On average, the deprivation gap in survival
for most cancers was larger in Scotland than in England and Wales
over the 15-year period 1986–2000 (data not shown). However, the
overall picture was very similar, namely a clear deprivation gap in
survival which has widened since the late 1980s.
Socioeconomic gradients in colorectal cancer survival may be
explained by differences in treatment (Faivre-Finn et al, 2002;
Guyot et al, 2005; Yu et al, 2005), stage at diagnosis (Singh et al,
2003) or comorbidity (Schrijvers et al, 1995a; Wrigley et al, 2005),
although such differences are not consistent (Ionescu et al, 1998;
Brewster et al, 2001; Wrigley et al, 2005). In Scotland, deprived and
affluent patients diagnosed during 1991–1994 had similar curative
resection rates, but survival was lower among deprived patients,
even after adjusting for stage at diagnosis and type of operation
(Hole and McArdle, 2002). Stage at diagnosis and treatment are the
most important influences on colorectal cancer survival, but their
interaction with deprivation remains unclear.
Melanoma of the skin has become increasingly common in the
more affluent, particularly women, probably due to an increased
ultra-violet exposure. Survival is high in the Nordic countries, but
also, uncharacteristically, in Scotland (Coleman et al, 2003),
probably due to a successful education campaign (MacKie et al,
2002) and the increasing proportion of thin tumours (MacKie et al,
1997). Despite the high 5-year survival, the deprivation gap in
relative survival remains substantial (6% in men, 4% in
women).T
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The deprivation gap in survival for breast and cervical cancer
was 4–5%, but it remained stable throughout the period 1986–
2000, as in England and Wales (Coleman et al, 2004). Population
screening programmes were introduced in Scotland for cervical
cancer in 1988 and breast cancer during the 1990s: uptake was
higher in more affluent groups, as has been observed in England
(Banks et al, 2002; Maheswaran et al, 2006), the United States
(Kothari and Birch, 2004), Canada (Katz and Hofer, 1994) and the
Netherlands (Louwman et al, 2007). Thus, 81% of affluent women
attended the breast-screening programme during 1999–2002,
compared to only 58% of deprived women (Information and
Statistics Division, 2006). Despite this, the deprivation gap in
breast cancer survival among women in the screening age range
fell from 3.7% for women diagnosed during 1986–1990 to 0.9%
for women diagnosed during 1996– 2000 (data not shown).
Prostate cancer incidence and survival increased rapidly since
the mid-1990s, both in the United Kingdom (Majeed et al, 2000;
Pashayan et al, 2006a, b) and in other countries (Etzioni et al, 2002;
Ciatto et al, 2005). The trends are partly attributable to increased
use of prostate-specific antigen (PSA) testing (Brewster et al,
2000), which identifies some cancers that would otherwise have
remained asymptomatic and nonlethal (Pashayan et al, 2006a, b).
The very rapid increase both in survival (11% every 5 years) and in
the deprivation gap in survival (reaching 6.9% in 1996–2000) is
very similar to the pattern observed in England and Wales
(Coleman et al, 2004), and appears likely to reflect unequal use of
the PSA test within different socioeconomic groups.
Bladder cancer survival increased between 1986–1990 and
1991– 1995, but then fell substantially for patients diagnosed
during 1996–2000. This appears to be due mainly to a change in
the coding of invasive bladder malignancy: in 1995, European
recommendations changed to reclassify some papillary urothelial
tumours as borderline malignancy (ICD-10 D41.4) or in situ (ICD-
10 D09.0), rather than invasive. As a result, incidence rates for
invasive malignancy of the bladder in Scotland fell by 50% in men
and 40% in women between 1996 and 2003 (Information and
Statistics Division, 2007). After removal of tumours that had been
reclassified as noninvasive, which have a much better prognosis,
recorded survival for invasive bladder cancers was lower. The
deprivation gap in survival also increased in the late 1990s,
reaching 7% by 1996–2000.
CONCLUSION
Cancer survival in Scotland has improved for all socioeconomic
groups, but the increase has been greater for more affluent groups,
and socioeconomic inequalities in survival have increased.
Possible explanations include widening socioeconomic differences
in stage at diagnosis and in access to optimal diagnosis and
treatment. The widening socioeconomic gap in cancer survival
cannot be attributed to increasing differences in background
mortality, since the use of relative survival with deprivation-
specific life tables removes these differences in the analysis. In the
context of increasing survival, however, socioeconomic differences
in comorbidity may also be relevant, particularly if they influence
the clinical decision to provide more effective but more aggressive
treatment.
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